Methylprednisolone succinate

Methylprednisolone succinate is a synthetic glucocorticoid and widely used as an anti-inflammatory agent. Methylprednisolone succinate is the prodrug of methylprednisolone. Methylprednisolone succinate can be studied in liver diseases[1][2][3].

Product Specifications

CAS Number

[2921-57-5]

Product Name Alternative

Methylprednisolone hydrogen succinate

UNSPSC

12352211

Hazard Statement

H360, H373

Target

Bacterial; Glucocorticoid Receptor

Type

Reference compound

Related Pathways

Anti-infection; Immunology/Inflammation; Vitamin D Related/Nuclear Receptor

Applications

Cancer-programmed cell death

Field of Research

Cancer; Inflammation/Immunology; Endocrinology

Assay Protocol

https://www.medchemexpress.com/Methylprednisolone_succinate.html

Purity

99.67

Solubility

DMSO : ≥ 100 mg/mL

Smiles

C[C@@]12[C@](C(COC(CCC(O)=O)=O)=O)(O)CC[C@@]1([H])[C@]3([H])C[C@H](C)C4=CC(C=C[C@]4(C)[C@@]3([H])[C@@H](O)C2)=O

Molecular Formula

C26H34O8

Molecular Weight

474.54

Precautions

H360, H373

References & Citations

[1]Marchant A, et al. Methylprednisolone differentially regulates IL-10 and tumour necrosis factor (TNF) productionduring murine endotoxaemia. Clin Exp Immunol. 1996 Oct;106 (1) :91-6.|[2]Diem R, et al. Methylprednisolone increases neuronal apoptosis during autoimmune CNS inflammation by inhibition of an endogenous neuroprotective pathway. J Neurosci. 2003 Aug 6;23 (18) :6993-7000.|[3]Ludwig, E. A., et al., (1993) . Pharmacokinetics of methylprednisolone hemisuccinate and methylprednisolone in chronic liver disease. Journal of clinical pharmacology, 33 (9), 805–810.